- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05229562
A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants
April 14, 2023 updated by: Biogen
An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB122 in Healthy Adult Japanese, Chinese, and Caucasian Participants
The study will be looking at an investigational drug, BIIB122, in healthy adult Japanese, Chinese, and Caucasian participants.
The main goal of the study is to compare the drug level achieved in the body, between the different ethnic groups, after single and multiple doses of BIIB122.
Researchers also want to see if single and multiple doses of BIIB122 are safe and if healthy participants can tolerate given doses of BIIB122.
Study Overview
Study Type
Interventional
Enrollment (Actual)
84
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Anaheim, California, United States, 92801
- Anaheim Clinical Trials, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Key Inclusion Criteria:
- Have a body mass index (BMI) between 18 and 30 kilograms per square meter (kg/m^2), inclusive. Body weight (BW) ≥50 kg and ≤100 kg at Screening
- Negative polymerase chain reaction (PCR) test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening and Day -1
- For Japanese healthy volunteers: Participant was born in Japan, and biological parents and grandparents were of Japanese origin; if living outside of Japan for more than 10 years, must not have significantly modified diet since leaving Japan
- For Chinese healthy volunteers: Participant was born in China, and biological parents and grandparents were of Chinese origin; if living outside of China for more than 5 years, must not have had a significantly modified diet since leaving China. Additionally, Chinese healthy volunteers must be of the same gender and have a screening weight within ±15% of their matched Caucasian healthy volunteer
- For Caucasian healthy volunteers: Participant must be a white person of European descent, which may include participants of Hispanic descent. Additionally, Caucasian healthy volunteers must be of the same gender and have a screening weight within ±15% of their matched Japanese healthy volunteer
Key Exclusion Criteria:
- History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal, or other major disease, as determined by the Investigator
- History of severe allergic or anaphylactic reactions, or of any allergic reactions that in the opinion of the Investigator are likely to be exacerbated by any component of the study treatment
- Current enrollment in any other drug, biological, device, or clinical study, or treatment with an investigational drug or approved therapy for investigational use within 30 days prior to Day -1, or 5 half-lives, whichever is longer
- Immunization or vaccinations are not allowed from Screening to safety follow-up (SFU)/ early termination (ET) Visit
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: Low-Dose
Participants will receive Dose 1 of BIIB122, orally, once on Day 1.
|
Administered as specified in the treatment arm.
Other Names:
|
Experimental: Cohort 2: Mid-Dose
Participants will receive Dose 2 of BIIB122, orally, once on Day 1.
|
Administered as specified in the treatment arm.
Other Names:
|
Experimental: Cohort 3: High-Dose
Participants will receive Dose 3 of BIIB122, orally, once on Day 1.
|
Administered as specified in the treatment arm.
Other Names:
|
Experimental: Cohort 4: High-Multi-Dose
Participants will receive Dose 3 of BIIB122, orally, once daily (QD), for 10 days.
|
Administered as specified in the treatment arm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum Observed Plasma Concentration (Cmax) of BIIB122
Time Frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
|
Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of BIIB122
Time Frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
|
Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
|
Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h) of BIIB122
Time Frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
|
Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10; Cohort 4: At multiple time points post-dose on Day 1, Pre-dose on Days 2 to 9, Pre-dose and at multiple time points post-dose on Days 10 to 13, and at Day 20
|
Cohorts 1,2 and 3: Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB122
Time Frame: Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10
|
Cohorts 1,2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10
|
Cohorts 1,2 and 3: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB122
Time Frame: Cohorts 1, 2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10
|
Cohorts 1, 2 and 3: At multiple time points post-dose on Days 1 to 4, and at Day 10
|
Cohort 4: Cmax of BIIB122 at Steady State (Cmax,ss)
Time Frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
|
Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
|
Cohort 4: Tmax of BIIB122 at Steady State (Tmax,ss)
Time Frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
|
Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
|
Cohort 4: AUC of BIIB122 Within a Dosing Interval at Steady State (AUCtau,ss)
Time Frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
|
Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
|
Cohort 4: Accumulation Ratio (AR) for AUC Within a Dosing Interval (AUCtau)
Time Frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
|
Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
|
Cohort 4: AR for Cmax
Time Frame: Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
|
Cohort 4: Pre-dose and at multiple time points post-dose on Days 10 to 13
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Cohorts 1,2 and 3: Up to Day 10; Cohort 4: Up to Day 20
|
An AE is any untoward medical occurrence in a participant or clinical investigation participant (healthy volunteer) administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
An SAE is any untoward medical occurrence that at any dose results in death, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect or is a medically important event.
|
Cohorts 1,2 and 3: Up to Day 10; Cohort 4: Up to Day 20
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 17, 2022
Primary Completion (Actual)
September 7, 2022
Study Completion (Actual)
September 7, 2022
Study Registration Dates
First Submitted
January 28, 2022
First Submitted That Met QC Criteria
January 28, 2022
First Posted (Actual)
February 8, 2022
Study Record Updates
Last Update Posted (Actual)
April 18, 2023
Last Update Submitted That Met QC Criteria
April 14, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 283HV101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer
-
Calico Life Sciences LLCAbbVieRecruitingHealthy VolunteerUnited States
-
BiogenRecruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
International Bio serviceNot yet recruiting
-
Angion Biomedica CorpQuotient SciencesNot yet recruitingHealthy VolunteerUnited States
-
University Hospital, ToursRecruitingNeurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults (PROSCEA)Healthy VolunteerFrance
-
BiogenCompleted
-
TeneoFour Inc.Novotech (Australia) Pty LimitedCompletedHealthy VolunteerAustralia
-
Spero TherapeuticsCompleted
Clinical Trials on BIIB122
-
BiogenDenali Therapeutics Inc.CompletedHealthy VolunteersUnited States
-
BiogenDenali Therapeutics Inc.RecruitingParkinson DiseaseUnited States, Netherlands, Italy, Spain, Israel, Canada, China, Germany, France, Austria, United Kingdom, Poland, Japan
-
BiogenDenali Therapeutics Inc.TerminatedParkinson DiseaseUnited States, Italy, Spain, Germany, France, United Kingdom
-
BiogenDenali Therapeutics Inc.Completed
-
BiogenCompleted